You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

28 search results for: lung function

expert video

What Is The COPD Vicious Cycle?

3 min

Pulmonology

Dr. Nicola Hanania explains the vicious cycle of exacerbations and lung function decline observed in COPD.

expert video

Impact of Exacerbations in COPD

2 min

Type 2 Inflammation

Dr. Stephanie Christenson discusses the association between COPD exacerbations and the increased risks of morbidity and mortality

expert video

ERS 2023 | Adult Asthma Symposium: Mini Debate

3 min

Pulmonology

Prof. Ian Pavord moderates a debate between Prof. Vibeke Backer and Dr. Francesca Puggioni about what a patient's lung function should be in order to be defined as achieving clinical remission in adult asthma.

expert video

Type 2 Inflammation Mediates Severe Asthma in Pediatric Patients

19 min

Pulmonology

Dr. Leonard Bacharier discusses how type 2 inflammation underlies the pathophysiology of pediatric severe asthma and contributes to burden.

expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

24 min

Pulmonology

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

expert video

What Differentiates COPD Exacerbations From Asthma Exacerbations?

2 min

Pulmonology

Join global expert Dr. Eric Bateman as he discusses how exacerbations in patients with COPD are different than exacerbations in patients with asthma.

interactivity

On-Treatment Asthma Remission: Moving Beyond Control

5 min

Pulmonology

Learn about the proposed framework for clinical remission in patients with asthma

expert video

Clinical Remission as a Goal in Asthma Clinical Practice

2 min

Pulmonology

Profs. Alberto Papi and Ian Pavord discuss clinical remission as a goal in asthma clinical practice beyond symptom control

Infographic

Mucus Plugging Is a Key Component of Remodeling in Asthma, Leading to Fixed Airway Obstruction

3 min

Pulmonology

Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma

interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

interactivity

Type 2 Inflammation Digital Assessment Tool

4 min

Pulmonology

Learn how to assess patients for the presence of uncontrolled asthma driven by underlying type 2 inflammation.

expert video

ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

42 min

Pulmonology

Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: IsraelChange country/region